Financial Survey: Lunai Bioworks (LNAI) and Its Peers

Lunai Bioworks (NASDAQ:LNAI) is one of 453 public companies in the “Pharmaceutical Preparations” industry, but how does it compare to its competitors? We will compare Lunai Bioworks to similar companies based on the strength of its earnings, profitability, analyst recommendations, dividends, risk, institutional ownership and valuation.

Profitability

This table compares Lunai Bioworks and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Lunai Bioworks	N/A	-378.07%	-210.59%
Lunai Bioworks Competitors	-2,625.49%	-359.57%	-43.35%

Institutional and Insider Ownership

71.4% of Lunai Bioworks shares are held by institutional investors. Comparatively, 39.4% of shares of all “Pharmaceutical Preparations” companies are held by institutional investors. 0.5% of Lunai Bioworks shares are held by company insiders. Comparatively, 14.1% of shares of all “Pharmaceutical Preparations” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of current ratings and price targets for Lunai Bioworks and its competitors, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lunai Bioworks	1	0	0	0	1.00
Lunai Bioworks Competitors	4822	9973	16010	372	2.38

As a group, “Pharmaceutical Preparations” companies have a potential upside of 107.47%. Given Lunai Bioworks’ competitors stronger consensus rating and higher possible upside, analysts plainly believe Lunai Bioworks has less favorable growth aspects than its competitors.

Risk & Volatility

Lunai Bioworks has a beta of 0.31, suggesting that its stock price is 69% less volatile than the S&P 500. Comparatively, Lunai Bioworks’ competitors have a beta of 10.21, suggesting that their average stock price is 921% more volatile than the S&P 500.

Earnings & Valuation

This table compares Lunai Bioworks and its competitors revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Lunai Bioworks	N/A	-$178.01 million	-18.43
Lunai Bioworks Competitors	$437.46 million	-$68.67 million	-10.44

Lunai Bioworks’ competitors have higher revenue and earnings than Lunai Bioworks. Lunai Bioworks is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Summary

Lunai Bioworks competitors beat Lunai Bioworks on 11 of the 13 factors compared.

Lunai Bioworks Company Profile

Enochian Biosciences, Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), influenza and coronavirus infections, and cancer. The company’s lead candidate includes ENOB-HV-01 for autologous HIV curative treatment; ENOB-HV-11, a preventative HIV vaccine; ENOB-HV-12, a therapeutic HIV vaccine; and ENOB-HB-01, a coopting HBV polymerase. Its pipeline development products comprise ENOB-DC-11 off the shelf DC vaccine for multiple solid tumors; and ENOB-DC-21, a non-specific vaccine for intraturmoral injection. Enochian Biosciences, Inc. has strategic partnerships with The Scripps Institute, Fred Hutchinson Cancer Research Center, the Texas Biomedical Research Institute, the University of California, Los Angeles, and The Hepatitis B Foundation and Baruch S. Blumberg Institute. The company was incorporated in 2017 and is headquartered in Los Angeles, California.